65 / 88
65
Thursday, 22 June 2017
/ Scientific Programme
WFSBP 2017
THU
002
ATP and NO interaction in stress models of
depression
Sâmia Joca, Brazil
003
The endocannabinoid and endovanilloid system in
stress-coping responses
Fabricio Moreira, Brazil
004
Neurotrophins and psychiatric disorders
Eero Castrén, Finland
T43: SCHIZOPHRENIA: BASIC/ CLINICAL
S-64
SYMPOSIUM
11:00–12:30
Auditorium 12
Operationalizing the dysconnection syndrome:
Translational approaches reveal brain network
dysfunction in schizophrenia
Chair:
Bernat Kocsis, USA
Co-Chair: Vaibhav Diwadkar, USA
001
Dysconnection in rodent models of schizophrenia:
Directed connectivity analyses of frequency-tagged
oscillatory coupling of frontal-hippocampal signals
Bernat Kocsis, USA
002
Ketamine disrupts the functional state of corti-
cothalamic systems: A mechanistic model for prodromal
schizophrenia
Didier Pinault, France
003
Structural and functional brain dysconnectivity
predating the onset of psychosis
Stefan Borgwardt, Switzerland
004
The dynamics of the functional “dysconnectome”
in schizophrenia: Network modeling of in vivo fMRI
signals
Vaibhav Diwadkar, USA
T24: NEUROPATHOLOGY
S-65
SYMPOSIUM
11:00–12:30
Auditorium 10
Cell-type specific epigenetic, proteomic and gene
expression signatures in schizophrenia: New findings
from post-mortem investigations
Chair:
Peter Falkai, Germany
Co-Chair: Andrea Schmitt, Germany
001
Alteration of genome-wide gene expression in
hippocampal CA4 pyramidal neurons in schizophrenia
Andrea Schmitt, Germany
002
Is the energy dysfunction observed in schizo-
phrenia brains being originated in oligodendrocytes?
Daniel Martins de Souza, Brazil
003
Integrated analysis of cell-type specific epigenome-
wide methylation changes in schizophrenia brains
Theo Kraus, Germany
A. Schmitt, J. Spanner, P. Falkai, A. Giese
004
Epigenetic signatures in the brain of schizophrenia
patients
Andre Fischer, Germany
T11: DEPRESSION: BASIC/ CLINICAL
S-67
SYMPOSIUM
11:00–12:30
B3 M1-M2
Spectrum of Mood Disorders (MD): Where is the place
for mixed states?
Chair:
Trisha Suppes, USA
002
Bipolar mixed states: Review of clinical presenta-
tion, treatment and outcomes
Mark Frye, USA
003
Major depressive disorder with mixed features:
Epidemiology, clinical characteristics and prognosis
Allan Young, United Kingdom
004
Major depressive disorder with mixed features:
Review of current treatment options
Trisha Suppes, USA
P-18
POSTER TOUR
13:00–14:30
Congress Hall A 1
Pharmacology & pharmacogenetics
Chair:
Dan Rujescu, Germany
001
In vitro inhibition of human cytochrome P450
isoenzymes by the novel atypical atipsychotic drug
iloperidone
Jacek Wójcikowski, Poland
P. Danek, W. A. Daniel
002
The stimulating effect of 5-HT2 receptor activation
in the hypothalamic arcuate nuclei (ARC) on cyto-
chrome P450 activity in rat liver
Marta Rysz, Poland
E. Bromek, A. Haduch, W. A. Daniel
003
Activation of 5-HT1A receptors in the hypothala-
mic Paraventricular Nuclei (PVN) negatively regulates
cytochrome P450 expression in rat liver
Anna Haduch, Poland
E. Bromek, M. Rysz, J. Wójcikowski, W. A. Daniel